Royalty Pharma Plc saw the highest growth of 1.16% in patent filings in April and 2.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.16% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Royalty Pharma Plc’s patent filings and grants. Buy the databook here.
Royalty Pharma Plc has been focused on protecting inventions in United States(US) with 11 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 43% filings and 33% grants. The United States(US), Australia(AU), European Patent Office(EPO), and Israel(IL) patent Office are among the top ten patent offices where Royalty Pharma Plc is filings its patents. Among the top granted patent authorities, Royalty Pharma Plc has 33% of its grants in United States(US), 17% in Australia(AU) and 17% in Israel(IL).
Roche and Johnson & Johnson could be the strongest competitors for Royalty Pharma Plc
Patents related to rare diseases and cell & gene therapy lead Royalty Pharma Plc's portfolio
Royalty Pharma Plc has the highest number of patents in rare diseases followed by, cell & gene therapy and climate change. For rare diseases, nearly 19% of patents were filed and 25% of patents were granted in Q2 2024.
Head and neck cancer related patents lead Royalty Pharma Plc portfolio followed by animal feed, and food
Royalty Pharma Plc has highest number of patents in head and neck cancer followed by animal feed, food, pet care, and clostridioides difficile infections (clostridium difficile associated disease).
For comprehensive analysis of Royalty Pharma Plc's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.